Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6361 USD | +2.58% | +9.31% | -54.89% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company shows low valuation levels, with an enterprise value at 0.09 times its sales.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-54.89% | 76.09M | - | ||
+48.54% | 56.61B | B- | ||
+37.15% | 39.25B | A | ||
-6.02% | 39.62B | B | ||
-6.90% | 28.28B | C | ||
+12.97% | 26.44B | B- | ||
-16.91% | 20.12B | B | ||
+31.71% | 12.48B | C+ | ||
+28.18% | 12.51B | B+ | ||
+0.38% | 12.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- PIII Stock
- Ratings P3 Health Partners Inc.